What ECG changes are expected in hypokalemia, hyperkalemia, hypocalcemia, and hypercalcemia, and how do calcium‑channel blockers and potassium‑channel blockers affect these ECG findings?

ECG Changes in Electrolyte Disorders

Your reasoning about potassium and calcium effects on the ECG contains several misconceptions that need correction: hypokalemia causes QT prolongation (not shortening), and calcium disorders affect the QT interval duration (not QRS amplitude or contractility directly).

Potassium Disorders

Hypokalemia

• Prominent U waves are the hallmark finding, often merging with T waves to create a bifid appearance 1, 2, 3
• QT interval prolongation occurs (contrary to your prediction of shortening) 2
• T wave amplitude decreases and ST segment depression develops 1
• In severe hypokalemia (K < 2.7 mmol/L), U wave amplitude may exceed T wave amplitude 1
• The bifid T wave pattern results from fusion of U waves with T waves, not from decreased potassium efflux 3

Your error: You predicted decreased QT interval, but hypokalemia actually prolongs the QT interval because reduced extracellular potassium impairs repolarization currents, particularly affecting regions with lower inward rectifier potassium current (IK1) 4, 2.

Hyperkalemia

• Peaked, tall, narrow-based T waves at K 5.5-7.0 mmol/L 2, 5
• Progressive QRS widening as potassium rises 6, 5
• Low P wave amplitude and eventual P wave loss 7
• "Sine wave" pattern in severe cases (>10 mmol/L) with risk of ventricular arrhythmias 2, 6
• Peaked T waves were the most common finding (36.2%) in a recent study, though 38.5% of hyperkalemic patients showed no ECG abnormalities 5

Your prediction was correct about peaked T waves in hyperkalemia 7, 2, 5.

Calcium Disorders

Hypocalcemia

• Prolonged ST segment and QT interval 2
• The QT prolongation occurs because calcium affects phase 2 (plateau) of the action potential
• Not related to decreased contractility or lower QRS amplitude as you suggested

Hypercalcemia

• Shortened ST segment and QT interval 2
• Again, this affects repolarization timing, not QRS amplitude or contractility

Your error: Calcium disorders affect the duration of the QT interval (repolarization time), not QRS amplitude. The QRS reflects ventricular depolarization and is not significantly altered by calcium levels. Contractility is a mechanical phenomenon separate from electrical conduction 8, 2.

Drug Effects: Clarifying Your Confusion

Calcium Channel Blockers

• These primarily affect cardiac contractility and AV nodal conduction
• They do not typically cause significant QT prolongation in the way you're thinking
• Calcium treatment for hyperkalemia works by restoring conduction velocity through calcium-dependent propagation, not by "membrane stabilization" 6

Potassium Channel Blockers

• You're correct that potassium channel blockers (like dofetilide, not "dodroneium") prolong QT interval
• They block IKr (rapid delayed rectifier current), which is essential for repolarization
• This mimics the effect of hypokalemia, which also impairs potassium currents 2

Key Mechanistic Points

The confusion in your reasoning stems from conflating:

1. Electrical conduction (what ECG measures) vs. mechanical contraction (pump function)
2. Depolarization (QRS) vs. repolarization (ST-T-U, QT interval)
3. Ion channel effects vs. contractility effects

Potassium primarily affects repolarization (T waves, U waves, QT interval), while calcium affects the plateau phase duration (QT interval length) 8, 2. Neither significantly alters QRS amplitude under typical clinical conditions.